Dramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer

---

Ak N., Vatansever S.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, cilt.46, sa.6, ss.1787-1791, 2021 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 46 Sayı: 6
• Basım Tarihi: 2021
• Doi Numarası: 10.1111/jcpt.13364
• Dergi Adı: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
• Sayfa Sayıları: ss.1787-1791
• Anahtar Kelimeler: atezolizumab, immunotherapy, microsatellite instability, ovarian cancer, PD-L1
• İstanbul Üniversitesi Adresli: Evet

Özet

What is known and objective: Patients with ovarian cancer have not benefited substantially from immunotherapy. We report a case of ovarian cancer, however, that responded well to the programmed cell death-ligand 1 inhibitor atezolizumab.